Ranked #829 of 8,699 institutional investors
Perceptive Advisors LLC
New York, NY
$4.97B
US stock portfolio at live prices · today −$19.4M (−0.39%)
Market closed. Prices as of Nov 20, 7:41 AM ET
- Value at quarter end (Q3 2026)
- $5.33B
- Change from Q2 2026
- −$1.10B (−17.08%)
- Positions
- 87 · 20 new, 19 sold out
- Filed
- Nov 16, 2026
Not counted in the ranking: call options on $39.3M of stock, put options on $361M, $11.7M of convertible notes and other principal-amount securities. $728M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesPRAX 12.7%SYRE 6.45%RYTM 5.96%AMLX 5.58%RLAY 4.08%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| PRAX Praxis Precision Medicines, Inc. | 2,024,781 | $630M | 12.7% | Reduced −1% |
| SYRE Spyre Therapeutics, Inc. | 3,280,943 | $320M | 6.45% | Reduced −24% |
| RYTM Rhythm Pharmaceuticals, Inc. | 2,532,556 | $296M | 5.96% | Reduced −2% |
| AMLX Amylyx Pharmaceuticals, Inc. | 10,573,735 | $277M | 5.58% | Added +27% |
| RLAY Relay Therapeutics, Inc. | 12,730,336 | $203M | 4.08% | Reduced −10% |
| CELC Celcuity Inc. | 3,179,794 | $179M | 3.61% | Reduced −1% |
| TVTX Travere Therapeutics, Inc. | 3,542,913 | $171M | 3.45% | Reduced −6% |
| EWTX Edgewise Therapeutics, Inc. | 4,138,282 | $170M | 3.43% | Reduced −5% |
| FRNM Freenome, Inc. | 12,606,053 | $125M | 2.52% | New |
| ORKA Oruka Therapeutics, Inc. | 1,072,363 | $105M | 2.11% | Reduced −20% |
| PTGX Protagonist Therapeutics, Inc. | 836,579 | $104M | 2.09% | Reduced −15% |
| KARD Kardigan, Inc. | 8,200,662 | $103M | 2.07% | Unchanged |
| INBX Inhibrx Biosciences, Inc. | 1,292,463 | $96.1M | 1.93% | Reduced −0% |
| ZYME Zymeworks Inc. | 3,545,501 | $95.2M | 1.92% | Reduced −15% |
| AVLN Avalyn Pharma Inc. | 2,675,296 | $76.8M | 1.55% | Unchanged |
| SLDB Solid Biosciences Inc. | 11,906,646 | $76.7M | 1.54% | Unchanged |
| BCRX BioCryst Pharmaceuticals, Inc. | 10,301,888 | $75.4M | 1.52% | Unchanged |
| NRIX Nurix Therapeutics, Inc. | 5,371,629 | $73.1M | 1.47% | Added +24% |
| RVMD Revolution Medicines, Inc. | 433,100 | $69.0M | 1.39% | Reduced −18% |
| WAT Waters Corporation | 135,000 | $61.6M | 1.24% | New |
| TNGX Tango Therapeutics, Inc. | 2,693,000 | $61.2M | 1.23% | Reduced −20% |
| ANRO Alto Neuroscience Inc | 1,760,950 | $46.7M | 0.94% | Added +9% |
| RGEN Repligen Corporation | 272,456 | $46.4M | 0.93% | Added +10% |
| LKFT Lakefront Biotherapeutics NV | 1,242,404 | $41.5M | 0.84% | New |
| AORT Artivion, Inc. | 2,112,290 | $39.1M | 0.79% | Added +22% |
| IRD Opus Genetics, Inc. | 9,000,000 | $36.7M | 0.74% | New |
| ABT Abbott Laboratories | 345,225 | $35.9M | 0.72% | New |
| OBIO Orchestra BioMed Holdings, Inc. | 5,037,606 | $35.3M | 0.71% | Unchanged |
| BLSM BlossomHill Therapeutics, Inc. | 1,812,193 | $26.1M | 0.53% | New |
| CRVS Corvus Pharmaceuticals, Inc. | 2,510,441 | $25.1M | 0.51% | Reduced −6% |
| NAUT Nautilus Biotechnology, Inc. | 11,564,744 | $25.1M | 0.51% | Reduced −1% |
| SEPN Septerna, Inc. | 567,479 | $22.2M | 0.45% | New |
| XFOR X4 Pharmaceuticals, Inc. | 7,350,491 | $21.8M | 0.44% | Reduced −7% |
| ELVN Enliven Therapeutics, Inc. | 462,506 | $21.5M | 0.43% | New |
| MMED MiniMed Group, Inc. | 1,320,000 | $21.5M | 0.43% | New |
| DYN Dyne Therapeutics, Inc. | 1,265,362 | $20.3M | 0.41% | Reduced −53% |
| SABS SAB Biotherapeutics, Inc. | 6,627,501 | $19.3M | 0.39% | Unchanged |
| CTMX CytomX Therapeutics, Inc. | 9,268,061 | $19.0M | 0.38% | Reduced −11% |
| AVR Anteris Technologies Global Corp. | 3,425,476 | $17.4M | 0.35% | Unchanged |
| EOLS Evolus, Inc. | 2,459,285 | $17.2M | 0.35% | Unchanged |
| RAPP Rapport Therapeutics, Inc. | 724,342 | $17.1M | 0.34% | Reduced −6% |
| IMVT Immunovant, Inc. | 519,345 | $16.9M | 0.34% | Reduced −62% |
| AXGN Axogen, Inc. | 280,000 | $15.8M | 0.32% | Added +13% |
| XERS Xeris Biopharma Holdings, Inc. | 933,671 | $15.5M | 0.31% | Added +100% |
| ANL Adlai Nortye Group Ltd. | 1,660,502 | $15.0M | 0.30% | Reduced −7% |
| DHR Danaher Corporation | 60,000 | $13.7M | 0.27% | Reduced −54% |
| SRZN Surrozen, Inc. | 439,685 | $13.5M | 0.27% | Reduced −13% |
| SCTX Scribe Therapeutics Inc. | 920,341 | $12.2M | 0.24% | New |
| MANE Veradermics Inc | 97,000 | $12.1M | 0.24% | New |
| VRDN Viridian Therapeutics, Inc. | 381,452 | $12.0M | 0.24% | Reduced −34% |
| YARW Yarrow Bioscience, Inc. | 813,098 | $11.6M | 0.23% | New |
| ADPT Adaptive Biotechnologies Corporation | 412,325 | $11.6M | 0.23% | Reduced −66% |
| MIRM Mirum Pharmaceuticals, Inc. | 115,391 | $11.0M | 0.22% | Unchanged |
| IRTC iRhythm Holdings, Inc. | 113,766 | $10.7M | 0.22% | Reduced −49% |
| DBVT DBV Technologies S.A. | 1,136,534 | $10.7M | 0.22% | Reduced −31% |
| GH Guardant Health, Inc. | 70,000 | $10.2M | 0.21% | Added +69% |
| GRAL GRAIL, Inc. | 96,911 | $10.2M | 0.20% | New |
| SPTX Seaport Therapeutics, Inc. | 500,000 | $9.2M | 0.18% | Unchanged |
| STRO Sutro Biopharma, Inc. | 970,846 | $8.5M | 0.17% | Reduced −26% |
| PALI Palisade Bio, Inc. | 8,425,065 | $7.8M | 0.16% | Unchanged |
| BBNX Beta Bionics, Inc. | 538,159 | $7.2M | 0.14% | Reduced −35% |
| BIIB Biogen Inc. | 28,030 | $6.9M | 0.14% | Reduced −90% |
| CAPR Capricor Therapeutics, Inc. | 850,000 | $6.4M | 0.13% | New |
| IVVD Invivyd, Inc. | 13,762,637 | $6.1M | 0.12% | Reduced −26% |
| ENGN enGene Therapeutics Inc. | 3,482,169 | $6.1M | 0.12% | Reduced −28% |
| ABVX ABIVAX Société Anonyme | 74,000 | $6.0M | 0.12% | Unchanged |
| BLLN BillionToOne, Inc. | 65,209 | $5.9M | 0.12% | Reduced −25% |
| NVCT Nuvectis Pharma, Inc. | 240,000 | $4.8M | <0.1% | Reduced −76% |
| LONA LeonaBio, Inc. | 1,859,322 | $4.6M | <0.1% | Unchanged |
| ADRX ADARx Pharmaceuticals, Inc. | 300,000 | $4.2M | <0.1% | New |
| OLMA Olema Oncology, Inc. | 575,000 | $4.1M | <0.1% | New |
| MOBI Mobia Medical, Inc. | 343,654 | $4.1M | <0.1% | Reduced −34% |
| AGMB AgomAb Therapeutics NV | 600,000 | $3.4M | <0.1% | Unchanged |
| UNH UnitedHealth Group Incorporated | 10,000 | $3.3M | <0.1% | Reduced −91% |
| CBLL Ceribell Inc | 98,779 | $2.5M | <0.1% | New |
| OM Outset Medical, Inc. | 833,333 | $2.4M | <0.1% | Unchanged |
| BRVE Braveheart Bio, Inc. | 115,000 | $2.2M | <0.1% | New |
| RVMDW Revolution Medicines, Inc. | 250,000 | $1.6M | <0.1% | Unchanged |
| ADMA ADMA Biologics, Inc. | 113,765 | $1.5M | <0.1% | Unchanged |
| OTLK Outlook Therapeutics, Inc. | 3,139,216 | $1.3M | <0.1% | Unchanged |
| EDSA Edesa Biotech, Inc. | 563,239 | $1.2M | <0.1% | Unchanged |
| MDLN Medline Inc. | 28,000 | $1.1M | <0.1% | Unchanged |
| SGMT Sagimet Biosciences Inc. | 67,674 | $651K | <0.1% | New |
| XGN Exagen Inc. | 114,893 | $437K | <0.1% | Unchanged |
| IBIT iShares Bitcoin Trust ETF | 12,000 | $421K | <0.1% | New |
| KPRX Kiora Pharmaceuticals, Inc. | 438,471 | $360K | <0.1% | Unchanged |
| ENSC Ensysce Biosciences, Inc. | 86,666 | $31K | <0.1% | Unchanged |
Sold out in Q3 2026
| Stock | Shares held at Q2 2026 | Worth today |
|---|---|---|
| CRL Charles River Laboratories International, Inc. | 140,000 | $45.9M |
| CORT Corcept Therapeutics Incorporated | 398,385 | $25.9M |
| ISRG Intuitive Surgical, Inc. | 51,884 | $21.1M |
| AXSM Axsome Therapeutics, Inc. | 118,450 | $16.1M |
| IONS Ionis Pharmaceuticals, Inc. | 566,000 | $15.4M |
| CTNM Contineum Therapeutics, Inc. | 1,255,592 | $11.4M |
| BSX Boston Scientific Corporation | 250,000 | $10.7M |
| OSCR Oscar Health, Inc. | 400,000 | $10.5M |
| NTRA Natera, Inc. | 34,689 | $10.1M |
| OMDA Omada Health, Inc. | 786,330 | $9.8M |
| TWST Twist Bioscience Corporation | 36,812 | $4.1M |
| CGEM Cullinan Therapeutics, Inc. | 426,478 | $3.9M |
| COGT Cogent Biosciences, Inc. | 121,082 | $3.4M |
| PHAT Phathom Pharmaceuticals, Inc. | 532,000 | $2.7M |
| SION Sionna Therapeutics, Inc. | 905,000 | $2.7M |
| TENX Tenax Therapeutics, Inc. | 1,700,000 | $2.4M |
| AVTX Avalo Therapeutics, Inc. | 219,813 | $1.5M |
| BDSX Biodesix, Inc. | 108,694 | $902K |
| CPIX Cumberland Pharmaceuticals Inc. | 96,982 | $611K |